Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Key Highlights
- ➤Candel (CADL) late-breaking PrTK05 abstract accepted for SITC 2026 poster presentation
- ➤November 7 poster will present longitudinal immune-profiling, biodistribution, and viral-shedding data
- ➤Aglatimagene remains investigational and is not FDA-approved or approved elsewhere
- ➤More than 1,000 patients have received aglatimagene in clinical trials to date
Expert Statements
Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics
“Longitudinal immune profiling in the PrTK05 trial of aglatimagene besadenovec plus valacyclovir with radiation therapy for localized intermediate-risk prostate cancer”
NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.
The presentation will feature longitudinal immune-profiling findings from PrTK05 (NCT07332000), together with biodistribution and viral shedding data, providing additional insights into the biological activity and characterization of aglatimagene in patients with localized intermediate-risk prostate cancer.
Get started
Create a free account to read the full story.